Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Siemens Healthineers AG    SHL   DE000SHL1006


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Siemens Healthineers : Partial IPO, resilient activity

share with twitter share with LinkedIn share with facebook
share via e-mail
01/30/2020 | 09:03am EST

Siemens Helthineers (hereafter "Helthineers") comprises the Siemens' healthcare group of businesses. Like SAP — discussed last week in this section — the company ranks as a prime investment candidate among MarketScreener's quantitative ratings.

Here, a peculiarity is that only 15% of equity capital was put on sale two years ago, while the Siemens mothership kept — as of now — the remaining 85% under control. Popular in Germany, these partial IPOs enable large conglomerates to monetize their assets in a timely fashion, and their subsidiaries to raise capital on their own.
Helthineers employs 52,000 people over 70 countries, and generates €14.5bn in revenue. Business is split into three segments: Medical Imaging (€8.9bn in revenue) sells scanner and radiography equipment, among others; Advanced Therapies (€1.6bn) develops high-precision surgical equipment, as well as linear particle accelerators used for radiotherapy treatments; finally, Diagnostics (€4.1bn) supplies laboratories with a comprehensive and integrated set of capabilities.  
Remarkably, within the first two segments the company operates as an oligopoly with GE and Philips. Growth rates outmatch GDPs, driven to a large extent by thriving demand from China and the Middle East. Margins are high and returns on capital employed highly rewarding, for business is mature and protected by unassailable barriers to entry.
The Diagnostics business remains more fragmented and competitive. Margins are less juicy but a total addressable market of €30bn exceeds Medical Imaging's (€19bn) and Advanced Therapies' (€3bn). Management intends to consolidate Helthineers's geographies and portfolio of services portfolio into a dominant offering — scale will make the difference — alongside the costly but promising launch of the Atellica suite.
Sluggish growth in Europe has been offset by continuing dynamism in North America, Middle East, Asia and the Oceania regions. Of course, the company's fortunes remain directly tied to government spending in healthcare, in particular where equipment rate lags behind — precisely the opposite of what happens in Europe, where hospitals are well provided and social security systems on the brink of insolvency.  
On the financial level, the restructuring plan deployed simultaneously with the IPO led to a staggering margin expansion (16% last year) in a short period of time. Going public certainly helped management to implement though but needed decisions — such as trimming redundant workforce — and deal with Siemens' redoutable unions.
Improved profitability should also cast light upon the company's excellent foundations. In addition to the high barriers to entry, all segments deliver recurring revenues and earnings — in Imaging and in Advanced Therapies with software licences, spare parts and maintenance services, and in Diagnostics where customers buy steady volumes of reagents and consumables.
Balance sheet is solid, with most of the loans (€4.1bn out of €4.5bn in total) granted by majority shareholder Siemens on preferred terms, and operating earnings covering interest charge by a factor of ten. So far, half of current indebtedness finances working capital requirements, while the other half was used for acquisitions. 
One should expect Siemens to progressively withdraw and let Helthineers tap the bond markets. Additional capital will be required, for management has high acquisitive ambitions, and a plan to replicate within the Diagnostics business the excellent competitive positions that have been established in Medical Imagery and Advanced Therapies. That strategy has a cost.
Shares trade at x23 2019 earnings, and x21 expected earnings by 2022. Albeit typical of a mature business growing slightly above GDP, these valuation levels give little credit to analysts' guidance — surveyed in real time by MarketScreener — which has been uplifted following the takeovers of ECG Management Consultants and Corindus in the United States.
With GE in trouble and Philips announcing its desire to solely focus on its healthcare business, it is obvious that management intend to get an upper hand with cross-support from financial markets and its former parent company, which next moves will be interesting to track. In effect, in a comparable case of partial IPO, Bayer took advantage of a momentous valuation frenzy to unload its 70% stake in Covestro. 
Siemens acting likewise would warrant a second look at Helthineers' investment case, whereas the former parent staying on board would signal that things go according to the plan. 

The editorial team
© MarketScreener.com 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
02/20SIEMENS HEALTHINEERS AG : Notification and public disclosure of transactions by ..
02/17SIEMENS HEALTHINEERS AG : Notification and public disclosure of transactions by ..
02/12SIEMENS HEALTHINEERS ANNUAL SHAREHOL : Profitable growth and commitment to Germa..
02/06SIEMENS HEALTHINEERS AG : Notification and public disclosure of transactions by ..
02/05Siemens Forms Crisis Team as Coronavirus Closes Chinese Factories -- Update
02/04SIEMENS HEALTHINEERS AG : Release of a capital market information
02/03EUROPE : European shares recover from dismal week, FTSE weathers Johnson's tough..
02/03WALL STREET STOCK EXCHANGE : Airbus settles, Boeing gets good news
02/03U.S. Futures Tick Higher As China Drops
02/03U.S. Futures Tick Higher As China Drops
More news
Surperformance© ratings
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Earnings quality
Business Predictability
P/E ratio
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
Bollinger Spread
Unusual Volumes
Financial Ratios

Size 2020e 2021e
Capitalization 40 386 M € -
Entreprise Value (EV) 44 814 M € 43 733 M €
Valuation 2020e 2021e
P/E ratio (Price / EPS) 24,0x 21,5x
Capitalization / Revenue 2,61x 2,49x
EV / Revenue 2,90x 2,76x
EV / EBITDA 14,4x 13,2x
Yield (DPS / Price) 2,18% 2,41%
Price to book (Price / BVPS) 3,82x 3,53x
Profitability 2020e 2021e
Operating Margin (EBIT / Sales) 16,1% 17,0%
Operating Leverage (Delta EBIT / Delta Sales) 1,30x 2,21x
Net Margin (Net Profit / Revenue) 10,8% 11,4%
ROA (Net Profit / Asset) 7,95% 8,27%
ROE (Net Profit / Equities) 16,9% 17,4%
Rate of Dividend 52,2% 51,9%
Balance Sheet Analysis 2020e 2021e
CAPEX / Sales   3,88% 3,64%
Cash Flow / Sales 11,4% 12,7%
Capital Intensity (Assets / Sales) 1,36x 1,38x
Financial Leverage (Net Debt / EBITDA) 1,42x 0,98x
Income Statement Evolution
EPS & Dividend
EPS Revisions
Revenue Revisions
Mean consensus HOLD
Number of Analysts 19
Average target price 42,40  €
Last Close Price 40,48  €
Spread / Highest target 28,5%
Spread / Average Target 4,76%
Spread / Lowest Target -8,59%
Consensus revision (last 18 months)